Gilead Sciences (GILD) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Gilead Sciences

NasdaqGS•Healthcare•Drug Manufacturers - General

$150.89+3.21(0.02%)Pre-market

Market Cap

$187.56B

P/S

6.2x

P/B

15.9x

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.

How this company scores

AverageMetricSide Score: 49/100

Strongest: Cash & Earnings Quality (25/25); weakest: Profitability (4/25).

Profitability4/25

Growth13/25

Balance Sheet & Red Flags7/25

Cash & Earnings Quality25/25

Strengths

Rising free cash flowCash-backed earningsConsistent free cash flowConsistent growth

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 18.4x5y range 12.1x – 823.2x

Currently near its 19-quarter median.

P/S · 6.2x5y range 2.7x – 6.2x

Currently above its 20-quarter median.

P/B · 15.9x5y range 3.8x – 15.9x

Currently above its 20-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

Operating margins dropped 125.0% over recent quarters — a sharp decline suggesting serious cost or pricing challenges.

Leverage Risk

Watch

D/E ratio of 2.0 is elevated and rising. Watch for further debt accumulation.

Price & Volume

Market Cap $187.56B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $30.46B
Q. Revenue: $7.80B
TTM EBITDA: $-2.50B
TTM Op. Income: $-2.50B
Q. Op. Income: $-10.39B
TTM Net Income: $-3.24B
Q. Net Income: $-10.50B
EPS: $-8.45
Shares Out.: $1.24B

$30.46B in TTM revenue grew 5.5% YoY, reaching $7.80B last quarter. TTM EBITDA of $-2.50B and TTM operating income of $-2.50B show growth is flowing through to the bottom line. However, net income is negative at $3.24B — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has risen for 5 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 79.8%
EBITDA Margin: -133.2%
Op. Margin: -133.2%
Net Margin: -134.5%

Op. margin of -133.2% is down 168.1% YoY — costs are rising relative to revenue. Net margin at -134.5% and gross margin of 79.8% show how much of each revenue dollar survives to profit. Over the past year, operating margin is down 481% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 6.2x
P/B Ratio: 15.9x

P/S of 6.2x and P/B of 15.9x. Across the last 7 quarters, P/E has risen for 2 consecutive quarters — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $49.36B
Cash: $3.18B
Long-Term Debt: $23.83B
Book Value: $11.83B
D/E Ratio: 2.0
Debt/EBITDA: N/A

With $49.36B in assets and $23.83B in long-term debt, D/E is 2.0and book value is $11.83B — elevated leverage, meaning significant financial risk in a downturn. Over the past year, debt/equity is up 79% — a weakening trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $3.57B
TTM Free Cash Flow: $12.94B
FCF Margin: 42.5%
FCF / Net Income: -4.0

TTM FCF of $12.94B on $3.57B in operating cash flow. The FCF / Net Income ratio of -4.0x means the business consumes cash — it is not yet self-funding. Across the last 8 quarters, free cash flow has risen for 3 consecutive quarters — an improving trend.